Key terms
About ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADCT news
Yesterday
6:16am ET
Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress
Apr 09
4:23pm ET
ADC Therapeutics Showcases Cancer Treatment Innovations
Apr 08
11:00pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 04
1:20pm ET
Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), TFF Pharmaceuticals (TFFP)
Apr 04
7:10am ET
ADC Therapeutics completes dose escalation in LOTIS-7 to treat r/r B-NHL
Mar 28
6:20am ET
ADC Therapeutics initiated with a Buy at Guggenheim
Mar 15
9:50pm ET
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 13
1:30pm ET
Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT) and Cresco Labs (OtherCRLBF)
Mar 13
12:00pm ET
ADC Therapeutics falls -13.5%
Mar 13
10:00am ET
ADC Therapeutics falls -20.2%
Mar 13
9:47am ET
ADC Therapeutics falls -15.3%
Mar 13
7:11am ET
ADC Therapeutics expects cash runway to extend into 4Q25
Mar 13
7:10am ET
ADC Therapeutics reports Q4 adjusted EPS (97c), consensus (50c)
Mar 06
6:37am ET
ADC Therapeutics: A Strong Buy on Promising Trial Results and Financial Stability
Mar 05
9:32am ET
ADC Therapeutics Shares Strategic Insights at Conferences
Feb 29
4:43pm ET
ADC Therapeutics Launches New Employee Incentive Plan
Feb 26
7:36am ET
RBC Capital Remains a Buy on ADC Therapeutics (ADCT)
Feb 20
6:27am ET
Buy Rating Affirmed for ADC Therapeutics with Raised Price Target Amid Promising Clinical Trials and Strong Balance Sheet
Feb 20
6:17am ET
ADC Therapeutics price target raised to $9 from $3 at H.C. Wainwright
Feb 14
12:00pm ET
ADC Therapeutics rises 14.7%
Jan 25
4:07am ET
ADC Therapeutics Strikes Key Deal with Redmile Group
No recent press releases are available for ADCT
ADCT Financials
Key terms
Ad Feedback
ADCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
